Replies to post #22173 on Cannabis Science Inc (fka CBIS)

[robhere]

You stopped talking to me awhile ago? You just responded again Hahaha you a funny dude, desperate at that. No its not true, you don't think CBIS will patent anything? and get their rights? for what they did? your crazy. All people know is that THC extracts kills skin cancer. what else is in it? CBIS knows.And ahead right now, If it was that easy people can just make some canna butter and rub it on their skin.

[SurgeGuy2.0]

Dude......I am getting a headache from your flip floping around...one minute you are bshing, the next pmping, and now bshing......which is it?

As for your statement:

Without FDA approval, CBIS has nothing.

You cannot be more wrong and you know it. I just outlined a few other areas of growth for CBIS....this is just one aspect...seems you have a very short-term memory loss or something....remember PTSD and Autism treatments as well as many others.....there is also a lot more to treatment than running down to the local pot store and buying an extract to slap on your face...come on now, you are better than that.....

If it was so easy, then why is Dr. Bob through the Phoenix Foundation being asked to help set-up the first school to train doctors on how to admisister and treat patients......alot more to CBIS than people realize IMO.....

[DouglasJH]

FDA approval may not be far off. Before then you will see a rescheduling.

Rescheduling will likely happen this year. In fact, natural THC has already been rescheduled this year, as long as it mirrors the synthetic THC.

The FDA is going to be forced to make some changes....not by scientific review but by political rule.

It is possible that before FDA allows sanctioned clinical trials, CBIS gets bought before out then. Companies like Sanofi-Aventis are looking for exactly what CBIS is offering. Sanofi-Aventis even has video on youtube describing the wonders of the endocannabiniod systems and looking for generic drug to fill out there profile of products.

Highlighting innovative drugmakers' recognition of revenue-earning opportunities in the off-patented medicines market, there have been a number of deals between research and development (R&D)-focused companies and generic drugmakers in recent years. The trend to acquire generic drugmakers began when US-based Mylan outbid Israel's Teva Pharmaceutical Industries to buy Merck KGaA 's generic drug unit for US$6.9bn in 2007. Following suit, Japanese drugmaker Daiichi Sankyo purchased a controlling stake in Indian generic drugs firm Ranbaxy Laboratories in 2008. With the aim of bolstering its emerging markets portfolio, GlaxoSmithKline (GSK) announced the purchase of a minority 10-25% stake in South Africa's Aspen Pharmacare in April 2009, as well as an alliance with Indian generic drugmaker Dr Reddy's . In 2010, Novartis announced its decision to acquire Ratiopharm .

Along with its long-standing generics interest Winthrop , which is largely based in Western Europe, multinational drugmaker Sanofi-Aventis has made a number of generic drugmaker acquisitions in emerging markets as it attempts to reduce its reliance on high-revenue-earning patented drugs. We see Sanofi's strategy for external growth as a sequence of well-positioned acquisitions, enabling it to gain wider geographic coverage and, of course, increase sales.

Strengthening Its Presence In Europe's Generic Medicines Market In 2009…

In early 2009, Sanofi-Aventis closed a US$2.3bn deal to purchase Zentiva , a Czech generic medicines firm, bolstering its presence in Central and Eastern Europe.

Story at http://www.corporatefinancingweek.com/file/101220/further-deals-with-generic-drugmakers-a-possibility-for-sanofi-aventis.html